Literature DB >> 2469536

Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.

D Goldstein1, S M Bushmeyer, P L Witt, V C Jordan, E C Borden.   

Abstract

The combined effects of tamoxifen, a competitive inhibitor of estrogen, and type I or II interferons on the proliferation of several human breast cancer cell lines in vitro were examined. Additive antiproliferative effects were observed with interferons and tamoxifen, in two estrogen receptor positive cell lines, MCF-7 and T-47D. In MCF-7 cells neither beta ser interferon, gamma interferon, nor alpha 6 interferon were able to significantly alter estrogen receptor levels. Antigrowth activities of beta ser interferon and gamma interferon in an estrogen receptor negative cell line, HS578T, were equivalent to those in estrogen receptor-positive cell lines. Consistent with the antiproliferative effects of interferons, high affinity beta ser interferon receptors and interferon inducible 2'5'-oligoadenylate synthetase were present in both MCF-7 and HS578T cell lines. Thus steroid hormone receptor status did not influence the antiproliferative effects of interferons on breast carcinoma cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469536

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Authors:  Yanxia Ning; Rebecca B Riggins; Jennifer E Mulla; Haniee Chung; Alan Zwart; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

Review 2.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

3.  Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.

Authors:  Dong Hoon Shin; Hye-Young Min; Adel K El-Naggar; Scott M Lippman; Bonnie Glisson; Ho-Young Lee
Journal:  Mol Cancer Ther       Date:  2011-10-06       Impact factor: 6.261

4.  Tamoxifen and interferon-beta for the treatment of metastatic breast cancer.

Authors:  L Repetto; P G Giannessi; E Campora; P Pronzato; A Vigani; C Naso; I Spinelli; P F Conte; R Rosso
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon.

Authors:  G Sica; G Dell'Acqua; F Iacopino; A Fattorossi; P Marchetti; T H van der Kwast; M Pavone-Macaluso
Journal:  Urol Res       Date:  1994

6.  Tamoxifen enhances interferon-regulated gene expression in breast cancer cells.

Authors:  D J Lindner; V Kolla; D V Kalvakolanu; E C Borden
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

7.  Interferon-alpha and gamma mediated gene responses in a human breast carcinoma cell line.

Authors:  R K Tiwari; G Y Wong; B Mukhopadhyay; N T Telang; J Liu; T B Hakes; M P Osborne
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

8.  Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.

Authors:  S P Robinson; D Goldstein; P L Witt; E C Borden; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1990-02       Impact factor: 4.872

9.  Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

Authors:  J E Macheledt; A U Buzdar; G N Hortobagyi; D K Frye; J U Gutterman; F A Holmes
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

10.  Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.

Authors:  D F Gibson; D A Johnson; D Goldstein; S M Langan-Fahey; E C Borden; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.